Bristol Files for Neoadjuvant Opdivo-Chemo-Surgery and Adjuvant Opdivo in Non-Small Cell Lung Cancer

 Applications based on results from CheckMate -77T, the company’s second positive Phase 3 randomized trial with an immunotherapy-based combination for the treatment of non-metastatic non-small cell lung cancer

The perioperative Opdivo-based regimen demonstrated significant improvement in event-free survival compared to neoadjuvant chemotherapy and placebo followed by surgery and adjuvant placebo

The U.S. Food and Drug Administration assigned a target action date of October 8

https://www.biospace.com/article/releases/bristol-myers-squibb-announces-acceptance-of-u-s-and-eu-regulatory-filings-for-neoadjuvant-opdivo-nivolumab-and-chemotherapy-followed-by-surgery-and-adjuvant-opdivo-in-resectable-non-small-cell-lung-cancer/